Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability

被引:108
作者
Alhamoruni, A. [1 ]
Wright, K. L. [2 ]
Larvin, M. [1 ]
O'Sullivan, S. E. [1 ]
机构
[1] Univ Nottingham, Sch Grad Entry Med & Hlth, Derby City Gen Hosp, Derby DE22 3DT, England
[2] Univ Lancaster, Div Biomed & Life Sci, Fac Hlth Med, Lancaster, England
关键词
intestinal permeability; inflammation; Caco-2; cells; cytokines; transepithelial electrical resistance (TEER); endocannabinoid; cannabinoid CB1 receptor; Delta(9)-tetrahydrocannabinol and cannabidiol; NECROSIS-FACTOR-ALPHA; GASTROINTESTINAL-TRACT; CB1; RECEPTORS; CELL-DEATH; BOWEL-DISEASE; CANNABIDIOL; ENDOCANNABINOIDS; SYSTEM; ACTIVATION; ANANDAMIDE;
D O I
10.1111/j.1476-5381.2011.01589.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND AND PURPOSE Activation of cannabinoid receptors decreases emesis, inflammation, gastric acid secretion and intestinal motility. The ability to modulate intestinal permeability in inflammation may be important in therapy aimed at maintaining epithelial barrier integrity. The aim of the present study was to determine whether cannabinoids modulate the increased permeability associated with inflammation in vitro. EXPERIMENTAL APPROACH Confluent Caco-2 cell monolayers were treated for 24 h with IFN gamma and TNF alpha (10 ng.mL(-1)). Monolayer permeability was measured using transepithelial electrical resistance and flux measurements. Cannabinoids were applied either apically or basolaterally after inflammation was established. Potential mechanisms of action were investigated using antagonists for CB1, CB2, TRPV1, PPAR gamma and PPAR alpha. A role for the endocannabinoid system was established using inhibitors of the synthesis and degradation of endocannabinoids. KEY RESULTS Delta(9)-Tetrahydrocannabinol (THC) and cannabidiol accelerated the recovery from cytokine-induced increased permeability; an effect sensitive to CB1 receptor antagonism. Anandamide and 2-arachidonylglycerol further increased permeability in the presence of cytokines; this effect was also sensitive to CB1 antagonism. No role for the CB2 receptor was identified in these studies. Co-application of THC, cannabidiol or a CB1 antagonist with the cytokines ameliorated their effect on permeability. Inhibiting the breakdown of endocannabinoids worsened, whereas inhibiting the synthesis of endocannabinoids attenuated, the increased permeability associated with inflammation. CONCLUSIONS AND IMPLICATIONS These findings suggest that locally produced endocannabinoids, acting via CB1 receptors play a role in mediating changes in permeability with inflammation, and that phytocannabinoids have therapeutic potential for reversing the disordered intestinal permeability associated with inflammation.
引用
收藏
页码:2598 / 2610
页数:13
相关论文
共 51 条
[1]   Special Issue: Guide to Receptors and Channels, 5th Edition Abstracts [J].
Alexander, Stephen P. H. ;
Mathie, Alistair ;
Peters, John A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2011, 164 :S1-+
[2]   Pharmacological Effects of Cannabinoids on the Caco-2 Cell Culture Model of Intestinal Permeability [J].
Alhamoruni, A. ;
Lee, A. C. ;
Wright, K. L. ;
Larvin, M. ;
O'Sullivan, S. E. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 335 (01) :92-102
[3]   Inflamed pouch mucosa possesses altered tight junctions indicating recurrence of inflammatory bowel disease [J].
Amasheh, Salah ;
Dullat, Sonja ;
Fromm, Michael ;
Schulzke, Joerg D. ;
Buhr, Heinz J. ;
Kroesen, Anton J. .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (10) :1149-1156
[4]   Early increase in intestinal permeability in patients with severe acute pancreatitis: Correlation with endotoxemia, organ failure, and mortality [J].
Ammori, BJ ;
Leeder, PC ;
King, RFGJ ;
Barclay, GR ;
Martin, IG ;
Larvin, M ;
McMahon, MJ .
JOURNAL OF GASTROINTESTINAL SURGERY, 1999, 3 (03) :252-261
[5]   Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy [J].
Barutta, Federica ;
Corbelli, Alessandro ;
Mastrocola, Raffaella ;
Gambino, Roberto ;
Di Marzo, Vincenzo ;
Pinach, Silvia ;
Rastaldi, Maria Pia ;
Perin, Paolo Cavallo ;
Gruden, Gabriella .
DIABETES, 2010, 59 (04) :1046-1054
[6]   Inflammatory bowel disease and the apical junctional complex [J].
Bruewer, Matthias ;
Samarin, Stanislav ;
Nusrat, Asma .
INFLAMMATORY BOWEL DISEASE: GENETICS, BARRIER FUNCTION, IMMUNOLOGIC MECHANISMS, AND MICROBIAL PATHWAYS, 2006, 1072 :242-252
[7]   Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice [J].
Capasso, R. ;
Borrelli, F. ;
Aviello, G. ;
Romano, B. ;
Scalisi, C. ;
Capasso, F. ;
Izzo, A. A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (05) :1001-1008
[8]   Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract [J].
Casu, MA ;
Porcella, A ;
Ruiu, S ;
Saba, P ;
Marchese, G ;
Carai, MAM ;
Reali, R ;
Gessa, GL ;
Pani, L .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 459 (01) :97-105
[9]   The gastrointestinal pharmacology of cannabinoids: an update [J].
Coutts, AA ;
Izzo, AA .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (06) :572-579
[10]   Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexus [J].
Coutts, AA ;
Irving, AJ ;
Mackie, K ;
Pertwee, RG ;
Anavi-Goffer, S .
JOURNAL OF COMPARATIVE NEUROLOGY, 2002, 448 (04) :410-422